Ng, Khong Y.

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., et al. (2019) · Science Translational Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 391

Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes

Chamberlain, S. J., Chen, P.-F., Ng, K. Y., Bourgois-Rocha, F., Lemtiri-Chlieh, F., Levine, E. S., & Lalande, M. (2010) · Proceedings of the National Academy of Sciences

Genetic Syndromes and ImprintingPluripotent Stem Cells Research

Cited by 312

Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma

Fernández de Larrea, C., Staehr, M., Lopez, A. V., Ng, K. Y., Chen, Y., Godfrey, W. D., Purdon, T. J., Ponomarev, V., Wendel, H.-G., Brentjens, R. J., et al. (2020) · Blood Cancer Discovery

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 223